The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...

The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma.

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

The FDA has accepted Merck's (MRK) supplemental NDA with priority review for its drug Welireg for the treatment of a rare ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

Cushing syndrome presents with a wide array of symptoms, many of which result from prolonged exposure to elevated cortisol ...

Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC. This review explores the ...

A study published in December 2024 demonstrates how natural language processing techniques, combined with dedicated human ...

Should we all be concerned about our cortisol levels? I took a blood stress test and spoke with experts to find out.

MicroRNAs (miRNAs) are endogenous small noncoding RNAs that regulate gene expression by either degrading or inhibiting the translation of mRNAs and have significant roles in the development of various ...

Brain cancer and other nervous system cancers have a 33.4% five-year survival rate. In adults, brain tumors rarely begin in the brain — when they do, they're known as primary brain cancers.